US FDA Draft Guidance Tells Medtech How To Recruit, Report Trial Subpopulations
This article was originally published in SRA
Executive Summary
Medical device makers should be prepared to identify and consider specific differences between patients of varying ages, races and ethnicities, and incorporate queries about subgroups into clinical trial designs and reports supporting 510(k) and premarket approval (PMA) submissions, the US Food and Drug Administration says in a guidance 1,2.
You may also be interested in...
US FDA Outlines Format For Race, Ethnicity Data Collection
The guidance document tells sponsors to ask about ethnicity before race, and provides suggested wording. It updates a 2005 guidance.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.